Authority cluster
What the verified publication set can and cannot establish about safety.
Atlas does not infer safety from absence of an adverse-event statement. The records below are included only when the verified publication set provides relevant human context or identifies material design limitations.
Publication records
Verified PubMed record for SS-31: Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice.
Verified PubMed record for SS-31: Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential.
Verified PubMed record for SS-31: SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting.
Verified PubMed record for SS-31: Elamipretide(SS-31) Attenuates Idiopathic Pulmonary Fibrosis by Inhibiting the Nrf2-Dependent NLRP3 Inflammasome in Macrophages.
Verified PubMed record for SS-31: Elamipretide (SS-31) treatment attenuates age-associated post-translational modifications of heart proteins.
Verified PubMed record for SS-31: Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.
Verified PubMed record for SS-31: Mitochondrial targeted therapy with elamipretide (MTP-131) as an adjunct to tumor necrosis factor inhibition for traumatic optic neuropathy in the acute setting.
Verified PubMed record for SS-31: Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.